Replies to post #29466 on Delcath Systems Inc (DCTH)

[JJAAMMAANN]

I am just as curious as to why now do the deal, but again, I am very glad they did. I have opened a pretty large position here, and am excited for the future.
I also just looked at the Clinical Trials.GOV website and see that they have another trial listed that is not yet recruiting?
"Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma" Maybe this will happen soon as well. It is a Phase3/4 trial.
Big things will be happening soon I am sure...just not sure what big thing that will be. Their other Phase 3 FOCUS trial is "Still Recruiting"..."Percutaneous Hepatic Perfusion vs. Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma (FOCUS)". Sure would be nice to know how many of the required 240 patients they have enrolled...or if they can go back to the FDA and ask for that N~Number to be reduced.
Time will tell, but 2018 looks to be very promising!
IMHO

[Potfolio]

The Warrants...

The new agreement says the warrants are 7M SHARES....@ 115% of closing price back in December ($0.03-$0.04). Where is everyone coming up with the 120M more warrants????


INFO BELOW

(b) warrants to purchase an aggregate of 7,000,000 shares of Common Stock (the “ New



The New Warrants bear the following terms:



• The Warrants will be exerciseable for five years from the date of issuance.



• The initial exercise price of the warrants is 115% of the closing bid price of the Company’s common stock as of the trading day ended immediately prior to the time of execution of the Exchange Agreement.




• The Warrants contain full antidilution ratchet protection from lowered price securities issuances subsequent to the date of issuance for six months from the date of issuance and most favored nations protection for a year from the date of issuance.



• The Warrants are exercisable on a cashless basis to the extent at any time commencing on the one year anniversary of the date of issuance the issuance of underlying securities is not covered by an effective registration statement.



• To the extent the investors elect to apply any amounts in their controlled accounts to the balances of the New Notes, the number of shares into which the applicable New Warrant is exercisable shall be reduced by a formula set forth in the New Warrants.